Yuchang Li

Testosterone replacement therapy in metabolic dysfunction-associated steatotic liver disease: a bench-to-bedside narrative review

TRT may represent a promising adjunctive therapy for reducing hepatic steatosis and improving the histopathological features of MASH in selected hypogonadal men with MASLD, particularly those with obesity or T2D and significant baseline steatosis; however, routine clinical use will require large, well-powered Phase 3 R...